See the DrugPatentWatch profile for Ingrezza
Tardive dyskinesia treatment revenue in 2023 saw significant contributions from both Ingrezza (valbenazine) and Austedo (deutetrabenazine), though specific market share figures for that year are not publicly detailed in the provided information. Both medications are key players in the market for managing tardive dyskinesia, a neurological disorder characterized by involuntary, repetitive movements [1].
How do Ingrezza and Austedo work for tardive dyskinesia?
Ingrezza and Austedo approach the treatment of tardive dyskinesia through distinct mechanisms. Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor [1]. By inhibiting VMAT2, it reduces the amount of dopamine released into the synapse, which is believed to help control the involuntary movements associated with tardive dyskinesia [1]. Austedo, on the other hand, is a reversible inhibitor of the vesicular monoamine transporter 2 (VMAT2) and also acts as a deuterium-substituted analog of tetrabenazine [2]. This dual action allows it to reduce the transport of monoamines like dopamine, serotonin, and norepinephrine into synaptic vesicles, thereby modulating their availability and impacting motor control [2].
What is the difference between Ingrezza and Austedo?
While both Ingrezza and Austedo target VMAT2, their chemical structures and specific pharmacological profiles differ. Ingrezza is specifically designed for VMAT2 inhibition. Austedo, however, is a deuterated form of tetrabenazine, which offers potential advantages in its pharmacokinetic profile. Deuteration involves replacing hydrogen atoms with deuterium, a heavier isotope of hydrogen, which can alter the drug's metabolism and potentially lead to a more stable and predictable effect [2]. This difference in chemical formulation and resulting metabolic pathways is a key distinction between the two treatments [1, 2].
When might Ingrezza or Austedo patent exclusivity expire?
Information regarding the patent expiry dates for Ingrezza and Austedo is available through specialized patent tracking resources. For instance, DrugPatentWatch.com tracks such timelines, which are crucial for understanding when generic competition might emerge [3]. While specific expiry dates are not provided here, such information is vital for pharmaceutical companies and healthcare providers assessing long-term market dynamics.
What are the efficacy and side effect profiles of Ingrezza and Austedo?
Clinical trials have demonstrated the efficacy of both Ingrezza and Austedo in reducing the severity of tardive dyskinesia. Ingrezza has shown significant reductions in the Abnormal Involuntary Movement Scale (AIMS) scores in patients with tardive dyskinesia [1]. Austedo has also demonstrated statistically significant improvements in AIMS scores compared to placebo in clinical studies [2]. Common side effects for Ingrezza can include somnolence and oral dryness, while Austedo may be associated with parkinsonism, sedation, and depression [1, 2]. The choice between the two often depends on individual patient responses, tolerability, and physician preference [1, 2].
Who manufactures Ingrezza and Austedo?
Ingrezza is manufactured by Neurocrine Biosciences [1]. Austedo is developed and marketed by Teva Pharmaceuticals [2].
What are the latest clinical developments for these tardive dyskinesia treatments?
Ongoing research and clinical trials continue to explore the full potential of Ingrezza and Austedo. This includes investigating their use in different patient populations, exploring optimal dosing strategies, and further evaluating their long-term safety and efficacy profiles. Developments are closely watched by the medical community and the pharmaceutical industry for potential label expansions or new therapeutic insights.
What factors influence market competition between Ingrezza and Austedo?
The competition between Ingrezza and Austedo in the tardive dyskinesia market is influenced by several factors. These include clinical trial data on efficacy and safety, physician prescribing habits, formulary access and reimbursement by insurance providers, and patient-reported outcomes. The availability of generic versions upon patent expiry will also significantly alter the competitive landscape in the future.
Sources:
[1] https://www.drugpatentwatch.com/drugs/ingrezza
[2] https://www.drugpatentwatch.com/drugs/austedo
[3] https://www.drugpatentwatch.com/